Abiopharma

🔍 Guttman-McCabe Christopher (Executive)

Company: Anterix Inc. (ATEX)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 40,000 shares of Common Stock at $34.72 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 84,876.00 | transaction_form_type: 4
• Sold 16,561 shares of Common Stock at $90.38 per share (Direct)
  Date: 2026-08-25 | Code: F | equity_swap_involved: 0 | shares_owned_after: 68,315.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,372 shares of Common Stock at $93.5863 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,943.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,791 shares of Common Stock at $92.7691 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,152.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 7,580 shares of Common Stock at $91.6945 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,572.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 2,696 shares of Common Stock at $90.6095 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 44,876.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 40,000 shares of Stock Option (Right to Buy) at $37.42 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2034-02-28 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: The Reporting Person exercised a stock option to purchase 40,000 shares of the Issuer's Common Stock for $37.42 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding an aggregate of 16,561 shares of the Issuer's Common Stock subject to the stock option to pay the exercise price and to satisfy its income tax withholding and remittance obligations in connection with the exercise of the stock option. The withholding of shares referenced here does not involve an open market sale of stock.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.215 to $93.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.265 to $92.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.205 to $91.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.01 to $90.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F6: The option shares are fully vested.